Summary Tamoxifen may mediate its effect in early breast cancer in part via an oestrogen receptor (ER)-independent pathway by directly stimulating fibroblasts to produce the negative paracrine growth factor transforming growth factor (TGF)-f,. We have previously shown that secretion of this factor is induced 3-to 30-fold in human fetal fibroblasts in vitro, and by stromal fibroblasts in vivo following tamoxifen treatment of ERpositive and ER-negative breast cancer patients. Primary cultures of breast tumour fibroblasts have been exposed to tamoxifen for 48 h, and rates of secretion of TGF-fl, and TGF-fl2 measured using a quantitative immunoassay. Fibroblast strains derived from malignant and benign tumours produced and secreted similar amounts of TGF-flp, but benign breast tumour fibroblasts secreted significantly higher levels of TGF-f32 compared with fibroblasts of malignant origin. Tamoxifen did not induce any consistent increase in TGF-,B secretion into the conditioned medium, but immunofluorescence analysis for the intracellular form of TGF-f3, revealed evidence of increased immunoreactive protein in tamoxifen-treated fibroblasts, which is localised to the nucleus. Therefore synthesis of TGF-fl, appears to be stimulated by tamoxifen, but increased secretion may be abrogated in vitro. Furthermore, using immunocytochemistry and transient transfection with an ER-responsive reporter construct, no ER was demonstrable in these fibroblasts supporting the proposed ER-independent paracrine pathway.
Initial results from the Nolvadex Adjuvant Trial Organisation (NATO) (1988) and Medical Research Council Scottish trials (1987) revealed that the efficacy of adjuvant tamoxifen in early breast cancer appeared to be independent of oestrogen receptor (ER) status. In the 8 year analysis of the NATO trial, division of patients according to ER status did not eliminate the favourable effects of tamoxifen treatment, and multivariate regression analysis did not show any significant difference in treatment effect between ERpositive and ER-negative patients. The more recent overview by the Early Breast Cancer Trialists Collaborative Group (1992) confirmed that ER status fails to select a group of patients who will not benefit from adjuvant tamoxifen therapy, and in particular reaffirmed that ER-negative patients obtain unequivocal benefit.
These counterintuitive results are difficult to reconcile with the classical mode of action of anti-oestrogens as competitive antagonists for the ligand binding site of the ER, a mechanism that is precluded in ER-negative cells (Terenius, 1968) . It was therefore proposed that tamoxifen directly stimulates fibroblasts to produce and secrete negative growth modulators, which act upon neighbouring malignant epithelial cells in a negative paracrine manner (Colletta et al., 1990) . Certain other observations contributed to formulation of this hypothesis; firstly, the timing of androgen receptor expression in the mesenchyme of the developing rodent prostate-androgen receptors are expressed on the mesenchyme of hormonally sensitive tissues before their expression of epithelial cells, implying that hormones can act indirectly upon epithelium (Cunha and Donjacour, 1987) . Secondly, skin fibroblasts from patients with a family history of breast cancer display fetal-like characteristics, thus alluding to some systemic abnormality of fibroblasts (Haggie et al., 1987) . Finally desmoids, which are pure mesenchymal tumours, undergo dramatic clinical response to tamoxifen and related triphenylethylenes, implying a direct effect of these agents upon fibroblasts (Brookes et al., 1992) .
There is now evidence for stromal induction of the negative growth modulator, transforming growth factor (TGF-f) both in vitro (Colletta et al., 1990 ) and in vivo (Butta et al., 1992) in response to tamoxifen. TGF-P is a member of a superfamily of regulatory peptides, existing as three isoforms TGF-fl,, TGF-f2 and TGF-#3 in mammalian species. These are multifunctional peptides that are usually stimulatory to cells of mesenchymal origin (Roberts et al., 1981) , but inhibitory to certain epithelia . This growth factor is involved in cellular proliferation and differentiation during development, and defective TGF-P signalling may be implicated in carcinogenesis (Roberts et al., 1988) . Specific roles for TGF-# in malignant predisposition and progression have been proposed, owing either to loss of sensitivity to TGF-# (Tucker et al., 1984) or defective intrinsic production by stromal cells, leading to reduced negative paracrine influences upon neighbouring epithelial cells (Benson and Baum, 1993 sample of a patient with benign breast disease, and these were considered to be normal skin fibroblasts. Specimens of tissue, collected at surgery, were washed immediately in RPMI-1640 medium following collection and excess fat trimmed off. Specimens were minced into small fragments (2-3 mm) and digested overnight with collagenase [type IIS (Sigma) 1 Mg ml-'] for a period of 24 h. The resulting cell suspension was centrifuged (580 g, 10 min) and the pellet was resuspended in complete medium, consisting of minimal essential medium (MEM) supplemented with 10% fetal calf serum (FCS), basic fibroblast growth factor (FGF) (25 ng ml-1), L-glutamine (2 mM), penicillin (1000 units ml-'), streptomycin (100 Mg ml-1) and fungizone (25 ng ml-1) (Freshney, 1987) . Flasks were incubated at 37°C, 100% humidity and 5% carbon dioxide. Cultures were left undisturbed for 3-4 days, after which time fibroblasts were seen to be attaching. Cells were passaged when cultures reached confluence after 10-14 days, and fibroblasts used between passages 5-10.
Verification offibroblast origin The identity of fibroblasts was confirmed not only by their characteristic morphology, but also by staining for the specific immunophenotype. Fibroblasts were seeded into slide flasks at a density of 105 cells ml-' and grown to 80-90% confluence, followed by fixation in ice-cold acetone. Following blocking of non-specific binding sites with 50% (v/ v) porcine serum in phosphate-buffered saline (PBS), cells were labelled with 5 Mg ml-1 of an anti-vimentin mouse primary antibody (Boehringer-Mannheim) and identified with 20 Mg ml-' of a secondary anti-mouse antibody conjugated to rhodamine. To verify that cultures were free from epithelial contamination, cells were labelled with 20 Mg ml-' of an anti-keratin primary antibody (ICN Immunobiologicals). Cells were photomicrographed using a BioRad MRC 600 Nikon confocal fluorescence microscope.
Oestrogen receptor content offibroblasts Transfection of fibroblasts-primary fibroblast strains were grown to 50 -60% confluence in 90 mm petri dishes in phenol red-free improved minimal essential medium (IMEM), containing 10% FCS [dextran-coated charcoal (DCC) treated] (Green and Leake, 1987) , FGF, L-glutamine, antibiotics and fungizone in the above concentrations. Cells were transiently transfected with the ER-responsive reporter construct ERE-tk-CAT, consisting of the oestrogen response element (ERE) (Kumar and Chambon, 1988) linked to a hymidine kinase promoter and the chloramphenicol acetyltransferase (CAT) reporter gene. Transfection was carried out using Lipofectin (Gibco BRL). As an internal control, cells were co-transfected with the pCH110 plasmid (Pharmacia), which contains the fl-galactosidase gene. As a positive control, cells were in addition triple transfected with the human ER expression vector pSG5-HEO (hER) (Green et al., 1986) . Each B isoforms JR Benson et at % 353 fibroblast strain was transfected with the ERE-tk-CAT construct in the presence of either 10 nM oestradiol or 1 gM tamoxifen. Internal controls were transfected with the pCH1 10 and ERE-tk-CAT constructs in the absence of any ligand, and positive controls with both ERE-tk-CAT together with hER.
Aliquots of 10 Mg of each type of DNA was added per dish, i.e. 20 ,g in total except for the positive controls, which received an additional 10 jug of hER. Cells were exposed to the lipofectin/DNA complex in serum-free medium for 24 h, followed by complete medium (containing 10% DCC-treated serum) for a further period of 48 h, after which cells were harvested for functional assays. CAT activity was measured in cell extracts using [3H]acetyl co-enzyme A (0.1 MCi) in a scintillation-based assay (Neumann et al., 1987) . CAT values were normalised to the fl-galactosidase levels, which were measured spectrophotometrically (Sambrook et al., 1989) .
Secretion of TGF-,B isoforms into conditioned media of fibroblasts Fibroblasts were seeded into 25 cm2 flasks in complete serum containing medium (MEM), and grown to subconfluence. Cells were washed twice with PBS and complete medium replaced with serum-free and phenol red-free medium supplemented with 5 ig ml-' bovine insulin and containing either 1 ,M tamoxifen or ethanolic vehicle (0.1%, v/v). Conditioned media (CM) were collected after a period of 48 h into siliconised vessels, clarified by centrifugation and stored at -70°C before sandwich enzyme-linked immunosorbent assay (SELISA). Cell monolayers were trypsinised, and cells harvested for counting. For SELISA analysis 1 ml samples of CM were thawed and treated with a cocktail of protease inhibitors to yield 1 Mg mlleupeptin, 1 Mg ml-' aprotonin, 1 Mg ml-' pepstatin, 120 Mg ml-1 phenylmethylsulphonyl fluoride (PMSF) and 100 Mg ml-1 bovine serum albumin.
Following precipitation of total protein from CM with 100% w/v trichloroacetic acid (TCA) protein pellets were washed with ether -ethanol (1:1, v/v) at 4°C and lyophilised before assay for TGF-/1 and TGF-fl2 using highly specific SELISAS (Danielpour et al., 1989; Flanders et al., 1990) .
Staining offibroblasts for the intracellular form of TGF-f3, Fibroblasts from breast tumours were grown in slide flasks to subconfluency in complete medium containing FCS. Cells were washed twice with PBS and 3 ml of serum-free and phenol red-free medium containing either 1 gM tamoxifen or ethanolic vehicle only added. After 48 h, media were discarded and cells fixed in ice-cold acetone. Non-specific binding sites were blocked with 50% (v/v) goat serum in PBS. Cells were exposed to primary polyclonal antibody to the intracellular form of TGF-,13 (either anti-LC antibody raised against amino acids 1-30 of the mature TGF-,B, or antiprecursor peptide raised against amino acids 266-278 of the TGF-f11 precursor23) at 10 Mg ml-' and incubated at 20°C for 2 h. Bound anti-TGF-f1, antibody was identified using a secondary anti-rabbit IgG conjugated to the fluorescent marker Texas red. Cells were mounted in glycerol, containing 0.1% 1 ,4-phenyldiamine, and visualised with confocal microscopy.
Results
Verification offibroblast origin Two fibroblast strains were stained with monoclonal antibodies to either vimentin or keratin. Oestrogen receptor content offibroblast Figure 2 shows the results of transiently transfecting four fibroblast strains derived from malignant breast tumours with an ER-responsive reporter construct. All four cell strains transfected with hER in the presence of its ligand (positive control, column 4) produce a high CAT signal, although the signal for one strain (D) is of relatively lower absolute value. In contrast, transfection of the ERE-tk-CAT construct without exogenous ER expression, either in the presence of E2 (column 2) or tamoxifen (column 3), yields a signal similar to the vehicle control (column 1).
These results are consistent with absence of ER protein or other transactivating proteins that function at the ERE from breast tumour fibroblasts, and are in agreement with our immunohistochemical examination of these cells for ER, which shows no specific staining (data not shown). This is in accordance with our previous data for fetal lung and pituitary fibroblasts (Colletta et al., 1990) and the data of others (Peterson et al., 1987) .
Secretion of TGF-f3 isoforms into conditioned media of fibroblasts
The rates of secretion of TGF-f,B and TGF-32 into the conditioned media of the eight fibroblast strains used in this study are shown in Table II . These values are the mean rates of secretion calculated for duplicate samples each based on either three (TGF-f,1) or two (TGF-f2) determinations, with a lower limit of detection of 0.5 pM. All cell strains derived Immunofluorescence offibroblasts for the intracellular form of TGF-B13
To further investigate TGF-,B synthesis in these cells, we employed immunofluorescence microscopy to examine the intracellular distribution and/or processing of TGF-,B after tamoxifen treatment. Figure 3 shows fibroblasts from a malignant breast tumour stained with the anti-LC (1 -30) antibody, which specifically reacts with the intracellular form of TGF-fl,1 (Flanders et al., 1989) , detected with a fluorescent secondary antibody. Cells in Figure 3a were treated with vehicle alone, whereas those in Figure 3b were treated with I gIM tamoxifen for 48 h before staining. Immunofluorescence analysis yields a distinctive pattern of staining in the nuclear region, and tamoxifen treatment of fibroblasts dramatically increases the intensity of this immunofluorescence ( Figure  3b ). This response was observed in all strains of breast tumour fibroblasts tested, together with A549 cells, which are known to be a rich source of TGF-fl, (Flanders et al., 1989 ).
Optical sectioning experiments in which confocal images are taken sequentially through the image plane indicate that this staining is indeed nuclear, and not confined to a peri-nuclear structure (Figure 4 ). To further confirm that the observed staining is attributable to TGF-#,, the same fibroblasts have been stained with an antibody raised to the precursor region of TGF-fl, (Flanders et al., 1989) . This antibody gives a broadly similar pattern of staining, and in particular there is a marked increase in intensity of nuclear staining following tamoxifen treatment (Figures 5a and b peptide was largely confined to stromal cells (Butta et al., 1992) . These findings are consistent with the hypothesis that stromal fibroblasts are directly stimulated to produce and secrete a negative growth modulator that acts upon neighbouring epithelial cells in a paracrine manner. The data also suggest a potential role for the extracellular matrix in 'recruiting' newly synthesised TGF-3,B adjacent to the tumour epithelium. The preservation of tissue organisation in these immunohistochemical studies is a great advantage over in vitro studies (Acland et al., 1990) . Other examples of nuclear localisation of common growth factors such as epidermal growth factor and colony-stimulating factor 1 have been reported (Johnson et al., 1980; Yeh et al., 1987; Scholl et al., 1994) . Therefore, fibroblasts may produce two forms of TGF-f3, one of which is destined for secretion and will act extracellularly via membrane receptors, and a second form that is localised/translocated to the nucleus. These secretory and nuclear forms of TGF-/31 could be differentially induced by tamoxifen. Relative amounts of the secretory form of TGF-P1 may be increased by tamoxifen in vivo (Butta et al., 1992) , but isolated fibroblasts in vitro may respond aberrantly to tamoxifen with increased amounts of the nuclear form. Attempts to determine the molecular mass of the cytoplasmic and nuclear forms of TGF-f31 by immunoblotting using the above antibodies were unsuccessful.
Control This increased intracellular staining for TGF-fl following tamoxifen treatment was also found in cells stained with anti-LC antibody and a secondary biotinylated antibody linked to a peroxidase-labelled avidin-biotin system. Furthermore, this response was observed in fibroblasts derived from both benign and malignant breast tumours, but not normal skin fibroblasts (data not shown). These findings suggest that fibroblasts from both benign and malignant tumours may display phenotypic features that are not shared by other somatic fibroblasts, and may be acquired during the process of neoplastic development. That phenotypic differences may exist between breast tumour fibroblasts and 'normal' fibroblasts is supported by the findings that conditioned media from benign and malignant breast tumours is stimulatory to MCF-7 cells in vitro, whereas media from normal skin fibroblasts is inhibitory to these cells (Adams et al., 1988) . Aberrant stromal phenotypes in breast tumours may lead to deranged stromal -epithelial interactions and promote neoplastic progression. Increased synthesis of TGF-/31 is not associated with any concomitant elevation of mRNA levels in MCF-7 breast cancer cells (Knabbe et al., 1987) or fetal fibroblasts (Colletta et al., 1990) . We have similar data from breast tumour fibroblasts in vitro (data not shown), and tamoxifen would therefore appear to enhance synthesis at a post-transcriptional level, although transcriptional mechanisms may also be operative depending on the local tissue levels of tamoxifen (Perry et al., 1995; Benson and Baum, 1996) and TGF-# isoform type (Arrick et al., 1994; MacCallum et al., 1994) .
The results of these in vitro investigations corroborate previous in vivo studies demonstrating induction of stromal TGF-fl, by tamoxifen. In particular, they confirm that breast tumour fibroblasts are a potential source of TGF-fl1, and despite limitations of in vitro data, evidence is presented for a direct effect of tamoxifen upon tumour fibroblasts in the absence of measurable oestrogen receptor. However, such induction of TGF-3,1 may not be a property unique to tamoxifen. Recently, up-regulation of extracellular TGF-,B has been observed in prostate cancer patients following various forms of ablative androgen therapy (Muir et al., 1994) . Therefore, TGF-# induction may be a common step in several therapeutic interventions which may not involve classical hormone receptors.
The challenge for the future is to develop agents that can modulate fibroblast behaviour, and are of a specificity and potency that renders them clinically efficacious. Such a strategy may be especially pertinent in a chemopreventive setting and in early-stage malignancies in which tumour burden is modest and cells still possess appropriate receptors for negative growth modulators such as TGF-f,.
